Axel Bolte
2021
In 2021, Axel Bolte earned a total compensation of $2.6M as President and Chief Executive Officer at Inozyme Pharma, a 51% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $250,960 |
|---|---|
| Option Awards | $1,734,309 |
| Salary | $544,205 |
| Other | $94,499 |
| Total | $2,623,972 |
Bolte received $1.7M in option awards, accounting for 66% of the total pay in 2021.
Bolte also received $251K in non-equity incentive plan, $544.2K in salary and $94.5K in other compensation.
Rankings
In 2021, Axel Bolte's compensation ranked 4,969th out of 12,406 executives tracked by ExecPay. In other words, Bolte earned more than 59.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,969 out of 12,406 | 60th |
Division Manufacturing | 2,087 out of 5,492 | 62nd |
Major group Chemicals And Allied Products | 891 out of 2,368 | 62nd |
Industry group Drugs | 798 out of 2,089 | 62nd |
Industry Pharmaceutical Preparations | 567 out of 1,536 | 63rd |
Source: SEC filing on April 27, 2022.
Bolte's colleagues
We found three more compensation records of executives who worked with Axel Bolte at Inozyme Pharma in 2021.